Table 1.

Basic characteristics of study participants.

N	103
Age (yrs)	55.5 (12.8)
Female, N (%)	52 (50%)
Black, N (%)	32 (31%)
Body Mass Index, (kg/m2)	27.8 (6.1)
ALMI Z-Score	−0.095 (1.17)
FMI Z-Score	0.28 (1.19)
Muscle Density Z-Score	−0.78 (1.13)
Visceral Fat Area (cm)	131.9 (74.2)
High Visceral Fat Area, N (%)	33 (32%)
Lower Leg Strength Z-Score	−0.29 (1.10)
Hand Grip Z-Score	−1.10 (1.25)
Knee Extension Strength (ft-lbs)	57.7 (30.1)
Knee Flexion Strength (ft-lbs)	28.3 (16.1)
RA Disease Characteristics
DAS28 (CRP)	4.00 (1.19)
HAQ Score	0.74 (0.61)
SPPB	11 (9, 12)
ACPA Positive, N (%)	84 (82%)
vdHS Score (N=92)	13.5 (3, 60)
Disease Duration, yrs	8.3 (2.6, 18.6)
Current Methotrexate, N (%)	68 (66%)
Current Biologic Therapy, N (%)	53 (51%)
Current Prednisone, N (%)	49 (48%)
Ever Methotrexate, N (%)	87 (86%)
Ever Biologic Therapy, N (%)	68 (66%)
Ever Prednisone, N (%)	81 (79%)

Results displayed as Mean(SD) or Median (IQR) for skewed data.

Mean and SD of all Z-Scores in controls are 0 +/− 1, by definition.

Abbreviations: ALMI= Appendicular Lean Mass Index; FMI= Fat Mass Index; RA= Rheumatoid Arthritis; DAS28(CRP)= Disease Activity Score of 28 joints including C-Reactive Protein; HAQ= Health Assessment Questionnaire; SPPB= Short Physical Performance Battery; ACPA= Anti-Citrullinated Peptide Antibody; vdHS= van der Heidje-Sharpe.